Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Pharmacometric and statistical considerations for dose optimization

Chotsiri P. et al, (2024), CPT: Pharmacometrics & Systems Pharmacology

Population pharmacokinetics of primaquine and its metabolites in African males.

Chotsiri P. et al, (2024), Malaria journal, 23

Cardiovascular concentration–effect relationships of amodiaquine and its metabolite desethylamodiaquine: Clinical and preclinical studies

Chan XHS. et al, (2023), British Journal of Clinical Pharmacology, 89, 1176 - 1186

Prevalence of physical activity counseling in primary care: A systematic review and meta-analysis.

Wattanapisit A. et al, (2023), Health promotion perspectives, 13, 254 - 266

Transcriptome profiling of male and female Ascaris lumbricoides reproductive tissues.

Phuphisut O. et al, (2022), Parasites & vectors, 15

Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers

Chotsiri P. et al, (2022), Clinical Pharmacology & Therapeutics, 112, 824 - 835

A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics.

Wattanakul T. et al, (2022), Expert Rev Clin Pharmacol

Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19

Assmus F. et al, (2022), Microorganisms, 10, 1639 - 1639

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2

Driouich J-S. et al, (2022), eBioMedicine, 82, 104148 - 104148

Pharmacokinetic considerations in seasonal malaria chemoprevention

Chotsiri P. et al, (2022), Trends in Parasitology

Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial

Peto TJ. et al, (2022), The Lancet Infectious Diseases, 22, 867 - 878

Mechanistic Modeling of Primaquine Pharmacokinetics, Gametocytocidal Activity, and Mosquito Infectivity

Chotsiri P. et al, (2022), Clinical Pharmacology & Therapeutics, 111, 676 - 685

Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2

Driouich J-S. et al, (2021)

Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy

Chotsiri P. et al, (2021), Antimicrobial Agents and Chemotherapy, 65

Evaluating the Impact of Intervention Strategies on the First Wave and Predicting the Second Wave of COVID-19 in Thailand: A Mathematical Modeling Study.

Mahikul W. et al, (2021), Biology, 10

Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children

Chotsiri P. et al, (2019), Nature Communications, 10

Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether‐Lumefantrine for Uncomplicated Malaria

Chotsiri P. et al, (2019), Clinical Pharmacology & Therapeutics, 106, 1299 - 1309

Transcriptome and excretory-secretory proteome of infective-stage larvae of the nematode Gnathostoma spinigerum reveal potential immunodiagnostic targets for development.

Nuamtanong S. et al, (2019), Parasite, 26

Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing

Ali AM. et al, (2018), Antimicrobial Agents and Chemotherapy, 62

Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin–piperaquine in healthy volunteers

Chotsiri P. et al, (2017), British Journal of Clinical Pharmacology, 83, 2752 - 2766

Load More

Include forthcoming?